Human inflammatory signaling pathways (N/A)

Human inflammatory signaling pathways are complex networks of molecular interactions that coordinate the body's response to harmful stimuli, such as pathogens or tissue injury (StatPearls, 'Inflammation', 2023). These pathways, which include the NF-κB, MAPK, JAK-STAT, and NLRP3 inflammasome cascades, regulate the production and activity of pro-inflammatory mediators like cytokines and chemokines (Nature Reviews Immunology, 'Signaling pathways in inflammation', 2017). While essential for host defense and tissue repair, chronic or dysregulated activation of these pathways is a primary driver of autoimmune diseases, chronic inflammatory conditions, and certain cancers (PubMed, 'Inflammatory signaling in disease', 2021). Therapeutic strategies often target specific nodes within these pathways, such as Tumor Necrosis Factor-alpha (TNF-α) or Janus kinases (JAK), to mitigate pathological inflammation (NIH, 'Targeting inflammatory pathways', 2022). However, because these pathways are also vital for normal immune surveillance and homeostasis, their pharmacological inhibition carries significant risks of systemic immunosuppression and increased susceptibility to opportunistic infections (Journal of Clinical Investigation, 'Safety of anti-inflammatory therapies', 2020). Consequently, drug development in this area focuses on achieving high specificity for pathological signaling while sparing protective immune functions.

Other names

Inflammatory cascadesPro-inflammatory signalingCytokine signaling networksInflammatory signaling pathways

Inhibition of pro-inflammatory cytokines, antagonism of cytokine receptors, or inhibition of intracellular signaling kinases (e.g., JAK, MAPK) and transcription factors (e.g., NF-κB).